Novartis washes its hands of another bispecific at the center of $2.5B Xencor deal
A centerpiece of Novartis’ $2.5 billion bispecifics deal with Xencor has been sidelined, the California biotech said in its third quarter earnings report Monday.
Novartis terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The move will take effect next February, Xencor said Monday. Xencor will drop development of the drug altogether as well, saying it has no future plans for in-house research.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.